Cited 112 time in
Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Le, Michael H. | - |
| dc.contributor.author | Devaki, Pardha | - |
| dc.contributor.author | Ha, Nghiem B. | - |
| dc.contributor.author | Jun, Dae Won | - |
| dc.contributor.author | Te, Helen S. | - |
| dc.contributor.author | Cheung, Ramsey C. | - |
| dc.contributor.author | Nguyen, Mindie H. | - |
| dc.date.accessioned | 2021-08-02T15:31:18Z | - |
| dc.date.available | 2021-08-02T15:31:18Z | - |
| dc.date.issued | 2017-03 | - |
| dc.identifier.issn | 1932-6203 | - |
| dc.identifier.issn | 1932-6203 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/20533 | - |
| dc.description.abstract | In the United States, non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and associated with higher mortality according to data from earlier National Health and Nutrition Examination Survey (NHANES) 1988-1994. Our goal was to determine the NAFLD prevalence in the recent 1999-2012 NHANES, risk factors for advanced fibrosis (stage 3-4) and mortality. NAFLD was defined as having a United States Fatty Liver Index (USFLI) > 30 in the absence of heavy alcohol use and other known liver diseases. The probability of low/high risk of having advanced fibrosis was determined by the NAFLD Fibrosis Score (NFS). In total, 6000 persons were included; of which, 30.0% had NAFLD and 10.3% of these had advanced fibrosis. Five and eight-year overall mortality in NAFLD subjects with advanced fibrosis was significantly higher than subjects without NAFLD ((18% and 35% vs. 2.6% and 5.5%, respectively) but not NAFLD subjects without advanced fibrosis (1.1% and 2.8%, respectively). NAFLD with advanced fibrosis (but not those without) is an independent predictor for mortality on multivariate analysis (HR = 3.13, 95% CI 1.93-5.08, p<0.001). In conclusion, in this most recent NHANES, NAFLD prevalence remains at 30% with 10.3% of these having advanced fibrosis. NAFLD per se was not a risk factor for increased mortality, but NAFLD with advanced fibrosis was. Mexican American ethnicity was a significant risk factor for NAFLD but not for advanced fibrosis or increased mortality. | - |
| dc.format.extent | 13 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Public Library of Science | - |
| dc.title | Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States | - |
| dc.type | Article | - |
| dc.publisher.location | United States | - |
| dc.identifier.doi | 10.1371/journal.pone.0173499 | - |
| dc.identifier.scopusid | 2-s2.0-85016303631 | - |
| dc.identifier.wosid | 000399174300007 | - |
| dc.identifier.bibliographicCitation | PLoS ONE, v.12, no.3, pp 1 - 13 | - |
| dc.citation.title | PLoS ONE | - |
| dc.citation.volume | 12 | - |
| dc.citation.number | 3 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 13 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
| dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
| dc.subject.keywordPlus | EXTERNAL VALIDATION | - |
| dc.subject.keywordPlus | HEPATIC STEATOSIS | - |
| dc.subject.keywordPlus | INDEX | - |
| dc.subject.keywordPlus | DIAGNOSIS | - |
| dc.subject.keywordPlus | ASSOCIATION | - |
| dc.subject.keywordPlus | POPULATION | - |
| dc.subject.keywordPlus | MARKERS | - |
| dc.subject.keywordPlus | SCORE | - |
| dc.identifier.url | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0173499 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
